Cas:1222-57-7 2-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine manufacturer & supplier

Chemical Name:2-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine

CAS.NO:1222-57-7

Synonyms:Zolimidine;Zolimidin;EINECS 214-947-4

Molecular Formula:C₁₄H₁₂N₂O₂S

Molecular Weight:272.32200

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.31 g/cm3

Index of Refraction:1.653

PSA:59.82000

Exact Mass:272.06200

LogP:3.48560

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Zolimidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 214-947-4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Zolimidine Use and application,Zolimidin technical grade,usp/ep/jp grade.

Related News: Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules. 2-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine manufacturer A week before Eli Lilly (LLY.N) disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters. 2-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine supplier A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. 2-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine vendor Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%. 2-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine factory A week before Eli Lilly (LLY.N) disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters.